Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab Expanded Access Program for Japanese Patients With Hereditary Angioedema
NCT04687137Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) Including Serious TEAEs and Adverse Events of Special Interest (AESI) at Day 294, Number of Participants With Clinically Significant Abnormalities in Clinical Laboratory Tests at Day 294 and 1 more. Started Feb 2021; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT04687137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04687137.